
EMA starts review of Gilead Sciences’ Zydelig following safety concerns
pharmafile | March 14, 2016 | News story | Research and Development, Sales and Marketing | EMA, Gilead Sciences, blood cancer, clinical trials, zydelig
Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports of deaths and side effects during clinical trials.
The European Medicines Agency (EMA) said the increased rate of serious adverse, was seen in three clinical trials, in a combination study with other cancer medicines.
The regulator said it review the data from these studies to assess whether the findings have any consequences for the authorised uses of Zydelig.
In the EU, Zydelig is authorised for the treatment of, chronic lymphocytic leukaemia. It is used in combination with rituximab. In addition, the drug is also indicated for a type of non-Hodgkin lymphoma called follicular lymphoma.
The European regulators advised careful monitoring of patients starting or on treatment with Zydelig for signs of infections. If Zydelig is well tolerated, treatment should not be stopped.
Anjali Shukla
Related Content

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …

Equity starts with listening: putting community voices at the centre of access
This article was developed and funded by Gilead Sciences Ltd. By Peter Wickersham, Vice President …

Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, …






